Skip to NavigationSkip to content

FDA approves Johnson & Johnson cataract treatment

Published on 04/12/19 at 11:38am

Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL).                                                                                                                             

The IOL will be used to treat patients with cataracts. It is a monofocal option for those with astigmatism, and it is the first product approved on the new TECNIS Toric II platform. The platform offers a range of options for different visual conditions and lifestyles.

The company are also conducting two post-market clinical trials to show the visual outcomes and the rotational stability provided by the platform. These trials will be conducted at 50 sites across the US and use 1,000 patients.

Xiao-Yun Song, Johnson & Johnson Vision Research and Development Global Head, said:

“With the launch of TECNIS Toric II IOL, our goal is to provide surgeons with a higher degree of confidence in treating astigmatism so that more cataract patients can enjoy clear, high quality vision. This advance represents the latest addition to out TECNIC family of IOLs, building on our proud history of raising the standard of care for patients with cataracts.”

More than 90% of people develop cataracts by the age of 65. Astigmatism is highly prevalent, affecting nearly half of the 24.4 million cataract patients in the US and it often goes untreated during cataract surgery. Toric IOLs are the most predictable method for correction.

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches